Haemonetics Corporation
HAE
$83.21 -0.87%
Exchange: NYSE | Sector: Healthcare | Industry: Medical Instruments Supplies
Q4 2025
Published: May 21, 2025

Earnings Highlights

  • Revenue of $330.60M down 3.7% year-over-year
  • EPS of $1.17 increased by 192.5% from previous year
  • Gross margin of 58.4%
  • Net income of 57.98M
  • ""Our industry-leading NexSys, TEG, and VASCADE technologies continue to propel our growth in attractive markets..." - Chris Simon" - Chris Simon
HAE
Haemonetics Corporation

Executive Summary

Haemonetics Corporation (HAE) reported robust financial performance in Q4 2025, delivering total revenue of $1.4 billion, representing a 4% growth year-over-year and a promising organic growth of 8% when excluding the impacts of the CSL divestiture and Whole Blood divestiture. This performance is attributed significantly to the hospital segment, now the largest business area, alongside significant recovery and margin expansion in the Plasma business. Management highlighted strong cash flow generation, with free cash flow growing 24% annually, underpinned by strategic initiatives aimed at optimizing the company's growth trajectory in the healthcare sector. Share buybacks totaling $150 million demonstrate confidence in future value creation and solidify the company's commitment to enhancing shareholder returns.

Key Performance Indicators

Revenue
Decreasing
330.60M
QoQ: -5.15% | YoY: -3.70%
Gross Profit
Increasing
193.05M
58.39% margin
QoQ: -0.26% | YoY: 12.50%
Operating Income
Increasing
71.34M
QoQ: 20.85% | YoY: 39.42%
Net Income
Increasing
57.98M
QoQ: 54.64% | YoY: 184.68%
EPS
Increasing
1.17
QoQ: 56.00% | YoY: 192.50%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 321.39 0.70 -4.4% View
Q4 2025 330.60 1.17 -3.7% View
Q3 2025 348.54 0.74 +3.7% View
Q2 2025 345.51 0.66 +8.6% View
Q1 2025 336.17 0.74 +8.0% View